Alerts
COVID-19 update
See our updated visitor policy, which allows 1 visitor per patient during exams only and includes masking for all. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab TG-1101 in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02656303

Study #:
STUDY00145131

Start Date:
Sep 13, 2017

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02656303

View Complete Trial Details & Eligibility at ClinicalTrials.gov